Obermatt
See Similar Stocks →

Moderna

NSQ:MRNA · US60770K1079
BiotechnologyX-Large

360

20
Profit price48
Owner Earnings Yield1
Dividend Yield1
Price/Sales25
Price/Book34
Return on Capital38
Cash Return on Capital26
Return on Equity31
EBIT Margin10
Gross Profitability17
Accruals87
Owner Earnings Margin23
Sales growth47
Profit growth1
Reinvestment67
Price momentum71
Debt load64
Refinancing14
Debt Payback1
Liquidity4
Analyst ratings9
Opinion Changes59
Price Target Upside4
Market mood24
Value Creation2/20not creating value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Moderna doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Profile

CountryUSA
IndustryBiotechnology
SizeX-Large
TypePublic Company
ExchangeNASDAQGS
Founded2016
Employees5,196
Websitemodernatx.com
ISINUS60770K1079
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)S&P 500 (USA)D.J. US Health Care
Themes
Infectious DiseasesImmunologyStem Cell TherapyOncologyVaccinesGeneticsRespiratoryArtificial IntelligenceBiotechnologyHealth CareMedicalPharmaceutical

Description

Moderna, Inc. operates as a biotechnology company. The company is advancing a new class of medicines made of messenger RNA (mRNA). mRNA medicines are designed to direct the body's cells to produce intracellular, membrane, or secreted proteins that h…

Analysis

Middle-of-the-road

Moderna, Inc. sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

Valuation data is not available for this company.

Growth is moderate; the safety picture is stretched. The company scores 2/20 on our value-creation score: not creating value.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
6
2026

All-time high

13

Mar 2026

All-time low

6

Jun 2026

Average rank

10

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
25
—
—
—
Price/Earnings
70
—
—
—
Price/Book
34
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
32
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Moderna with its peers
Maravai LifeSciences Holdings
NSQ:MRVI
35
CountryUSA
IndustryLife Sciences Tools & Services
SizeMedium
Full Stock Analysis →
Enanta Pharmaceuticals
NSQ:ENTA
62
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Novavax
NSQ:NVAX
23
CountryUSA
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
Opus Genetics
NAQ:IRD
52
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
Sarepta Therapeutics
NSQ:SRPT
69
CountryUSA
IndustryBiotechnology
SizeLarge
Full Stock Analysis →
Mirum Pharmaceuticals
NMQ:MIRM
40
CountryUSA
IndustryBiotechnology
SizeMedium
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →